- Home
- Cardiology
- Triheptanoin in the Management of Long-Chain Fatty Acid Oxidation Disorders: Mechanism, Clinical Evidence, and Positioning
6d3 min read
Medical Article
Introduction: Long-chain fatty acid oxidation disorders (LC-FAODs) represent a group of rare, life-threatening, inborn errors of metabolism that prevent the body from converting long-chain fatty acids (LC-FAs) into energy during periods of fasting and physiological stress (1). LC-FAODs are caused by mutations in genes encoding mitochondrial enzymes

Triheptanoin in the Management of Long-Chain Fatty Acid Oxidation Disorders: Mechanism, Clinical Evidence, and Positioning
5 Reached
Similar Content

Characteristics, Outcomes and Predictors of Long-Term Mortality for Patients Hospitalized for Acute Heart Failure
150 Reached

ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes

Catheter Ablation for Atrial Fibrillation with HF
691 Reached

Patient with History of Atrial Fibrillation
519 Reached3 Likes

Young Girl Presented with Irritability and Abnormal Behavior
2254 Reached10 Comments4 Likes
